We are dedicated to developing novel vaccines that induce durable and long-term immunity. We believe that our pipeline and vaccine platform are synergistic for developing next generation preventive vaccines to improve both health outcomes and quality of life globally.

 

Our versatile vaccine platform has unique molecular properties that enables delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines.

 

Our lead influenza vaccine program uses proprietary technology developed at the University of Oxford to identify specific epitopes with cross-reactive proprieties, that enables the potential development of a universal flu vaccine.